A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Latest Information Update: 17 Nov 2025
At a glance
- Drugs Bromophenoxyazole propanoic acid (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Therapeutic Use
- Acronyms ESTABLISH1; SYNAPSE-CMT
Most Recent Events
- 12 Nov 2025 Actual primary completion date changed to 28 Oct 2025.
- 12 Nov 2025 Status changed from active, no longer recruiting to completed.
- 23 Oct 2025 Planned End Date changed from 16 Mar 2026 to 1 Dec 2025.